2-((2-(cyclopropylmethyl)phenoxy)methyl)-4,5-dihydro-1H-imidazole | 1448331-75-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-((2-(cyclopropylmethyl)phenoxy)methyl)-4,5-dihydro-1H-imidazole
• 英文别名: 2-[[2-(cyclopropylmethyl)phenoxy]methyl]-4,5-dihydro-1H-imidazole
• CAS: 1448331-75-6
• 化学式: C₁₄H₁₈N₂O
• 分子量: 230.31
• InChiKey: OTXMFMMMNBKXQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(环丙基甲基)-苯酚 在 三甲基铝 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 正己烷 、 甲苯 为溶剂， 反应 31.0h， 生成 2-((2-(cyclopropylmethyl)phenoxy)methyl)-4,5-dihydro-1H-imidazole
  参考文献：
  名称：

  Exploring Multitarget Interactions to Reduce Opiate Withdrawal Syndrome and Psychiatric Comorbidity

  摘要：

  Opioid addiction is often characterized as a chronic relapsing condition due to the severe somatic and behavioral signs, associated with depressive disorders, triggered by opiate withdrawal. Since prolonged abstinence remains a major challenge, our interest has been addressed to such objective. Exploring multitarget interactions, the present investigation suggests that 3 or its (S)-enantiomer and 4, endowed with effective alpha(2C)-AR agonism/alpha(2A)-AR antagonism/5-HT1A-R agonism, or 7 and 9-11 producing efficacious alpha(2C)-AR agonism/alpha(2A)-AR antagonism/I-2-IBS interaction might represent novel multifunctional tools potentially useful for reducing withdrawal syndrome and associated depression. Such agents, lacking in sedative side effects due to their alpha(2A)-AR antagonism, might afford an improvement over current therapies with clonidine-like drugs.

  DOI：

  10.1021/ml400232p

文献信息

• Exploring Multitarget Interactions to Reduce Opiate Withdrawal Syndrome and Psychiatric Comorbidity
  作者：Fabio Del Bello、Eleonora Diamanti、Mario Giannella、Valerio Mammoli、Laura Mattioli、Federica Titomanlio、Alessandro Piergentili、Wilma Quaglia、Marco Lanza、Chiara Sabatini、Gianfranco Caselli、Elena Poggesi、Maria Pigini

  DOI：10.1021/ml400232p

  日期：2013.9.12

  Opioid addiction is often characterized as a chronic relapsing condition due to the severe somatic and behavioral signs, associated with depressive disorders, triggered by opiate withdrawal. Since prolonged abstinence remains a major challenge, our interest has been addressed to such objective. Exploring multitarget interactions, the present investigation suggests that 3 or its (S)-enantiomer and 4, endowed with effective alpha(2C)-AR agonism/alpha(2A)-AR antagonism/5-HT1A-R agonism, or 7 and 9-11 producing efficacious alpha(2C)-AR agonism/alpha(2A)-AR antagonism/I-2-IBS interaction might represent novel multifunctional tools potentially useful for reducing withdrawal syndrome and associated depression. Such agents, lacking in sedative side effects due to their alpha(2A)-AR antagonism, might afford an improvement over current therapies with clonidine-like drugs.